Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...
The early to mid-stage dose-ranging study evaluated the safety and efficacy of the candidate in patients with SMA with three ...
Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.
These regions contain hundreds of genes critical to human health—including those implicated in spinal muscular atrophy (SMN1/SMN2), congenital adrenal hyperplasia (CYP21A2), and red-green color ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results